File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A multi-centered, randomized, double-blind placebo controlled study of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women

TitleA multi-centered, randomized, double-blind placebo controlled study of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women
Authors
Issue Date2004
PublisherSpringer
Citation
International Osteoporosis Foundation (IOF) World Congress on Osteoporosis, Rio de Janeiro, Brazil, 14-18 May 2004. In Osteoporosis International, 2004, v. 15 n. S1, p. S96 Abstract no. P356SU How to Cite?
AbstractRisedronate has been shown to be effective in preventing fractures in Caucasian women. To assess the efficacy and tolerability of Risedronate 5 mg/d versus placebo in Chinese postmenopausal women, we studied 65 osteoporotic women with BMD T score £2.5 at the spine. BMD at L1-4 lumbar spine, femoral neck and total hip region, serum osteocalin and urine N-telopeptide were assessed at 3 monthly intervals. No difference in BMD and bone turnover markers was observed at baseline between the 2 groups. Risedronate significantly increased BMD at 3 months [lumbar spine 3.5% (p<0.0001), femoral neck 1.9% (p<0.02), total hip 2.7% (p<0.0001)], and 12 months [lumbar spine 6.2% (p<0.0001), femoral neck 1.9% (p<0.02), total hip 2.7% (p<0.0001)], whereas no difference in BMD was seen in the placebo group. Risedronate significantly decreased osteocalcin by means of 2.9% and 11.4% and N-telopeptide by means of 31.7% and 40.1% at 3 and 6 month respectively from placebo. Signifi- cant differences were already observed at the lumbar spine BMD and urinary N-telopeptide at month 3 between the 2 treatment groups. The change in NTx at 3 months correlated to the change in BMD at 12 months. In conclusion, as similar to Caucasian women, early efficacy of Risedronate on BMD and bone turnover markers is seen in postmenopausal osteoporotic Asian women.
Persistent Identifierhttp://hdl.handle.net/10722/101369
ISSN
2015 Impact Factor: 3.445
2015 SCImago Journal Rankings: 1.460

 

DC FieldValueLanguage
dc.contributor.authorKung, AWCen_HK
dc.contributor.authorIp, TPen_HK
dc.contributor.authorLeung, Jen_HK
dc.contributor.authorLee, Gen_HK
dc.contributor.authorHo, AYYen_HK
dc.date.accessioned2010-09-25T19:46:51Z-
dc.date.available2010-09-25T19:46:51Z-
dc.date.issued2004en_HK
dc.identifier.citationInternational Osteoporosis Foundation (IOF) World Congress on Osteoporosis, Rio de Janeiro, Brazil, 14-18 May 2004. In Osteoporosis International, 2004, v. 15 n. S1, p. S96 Abstract no. P356SUen_HK
dc.identifier.issn0937-941X-
dc.identifier.urihttp://hdl.handle.net/10722/101369-
dc.description.abstractRisedronate has been shown to be effective in preventing fractures in Caucasian women. To assess the efficacy and tolerability of Risedronate 5 mg/d versus placebo in Chinese postmenopausal women, we studied 65 osteoporotic women with BMD T score £2.5 at the spine. BMD at L1-4 lumbar spine, femoral neck and total hip region, serum osteocalin and urine N-telopeptide were assessed at 3 monthly intervals. No difference in BMD and bone turnover markers was observed at baseline between the 2 groups. Risedronate significantly increased BMD at 3 months [lumbar spine 3.5% (p<0.0001), femoral neck 1.9% (p<0.02), total hip 2.7% (p<0.0001)], and 12 months [lumbar spine 6.2% (p<0.0001), femoral neck 1.9% (p<0.02), total hip 2.7% (p<0.0001)], whereas no difference in BMD was seen in the placebo group. Risedronate significantly decreased osteocalcin by means of 2.9% and 11.4% and N-telopeptide by means of 31.7% and 40.1% at 3 and 6 month respectively from placebo. Signifi- cant differences were already observed at the lumbar spine BMD and urinary N-telopeptide at month 3 between the 2 treatment groups. The change in NTx at 3 months correlated to the change in BMD at 12 months. In conclusion, as similar to Caucasian women, early efficacy of Risedronate on BMD and bone turnover markers is seen in postmenopausal osteoporotic Asian women.-
dc.languageengen_HK
dc.publisherSpringer-
dc.relation.ispartofOsteoporosis Internationalen_HK
dc.titleA multi-centered, randomized, double-blind placebo controlled study of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese womenen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailKung, AWC: awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00198-004-1620-7-
dc.identifier.hkuros87838en_HK
dc.identifier.volume15en_HK
dc.identifier.issueS1en_HK
dc.identifier.spageS96en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats